资金将主要用于共聚焦显微内镜产品的持续研发、规模化生产、临床应用推广及全球商业化推进。 11月24日，精微视达医疗科技有限公司（以下简称"精微视达"）宣布完成新一轮融资，本轮融资由倚锋 灼华基金、华彬沣泰私募基金、长飞产业基金联合投资完成，金额超亿元。 ...

#工业富联表示将调整回购价格上限#【工业富联：将尽快召开董事会调整回购价格上限】#工业富联股 价自最高点跌30%#有投资者问工业富联，公司最近股价一路下跌，从最高点已跌30％，请问公司是否 有回购计划及实施进度？工业富联在互动平台表示，公司2025年第一次临时股东大会审议通过的回购股 份价格上限为不超过20元/股，经2024年年度权益分派后调整为不超过19.36元/股。后续，公司将尽快召 开董事会调整回购价格上限，并加速推进回购事项。（智通财经） ...

Core Insights - Xiaopeng Motors celebrated the production of its one millionth vehicle and the delivery of the first batch of X9 Super Extended Range vehicles, achieving this milestone in just 14 months after the previous half-million mark, which took 82 months to reach [1][3] Group 1: Company Milestones - The CEO of Xiaopeng Motors, He Xiaopeng, defined the one million vehicle milestone as a new level for the company, emphasizing a focus on safety, quality, service, and operational systems as core responsibilities [3] - Xiaopeng Motors reiterated its new brand positioning as a "mobility explorer in the physical AI world, a globally embodied intelligent company" during the recent Guangzhou Auto Show [5] Group 2: Technological Advancements - At the "2025 Technology Day," Xiaopeng Motors showcased breakthroughs in the physical AI field, announcing four AI applications, including the second-generation VLA, Robotaxi, a new generation of IRON, and two types of flying cars, all set to enter mass production by 2026 [5] - The second-generation VLA model is expected to facilitate the transition from L2 level assisted driving to L4 level advanced autonomous driving [5] Group 3: Sales Performance - From January to October 2025, Xiaopeng Motors achieved cumulative deliveries of 355,209 vehicles, representing a year-on-year increase of 190%, with overseas deliveries reaching 34,712 units, a year-on-year increase of 106.7% [5]

上述行为违反了本所《股票上市规则（2024年修订）》第1.4条、第2.1.1条、第6.3.6条、第6.3.19条的规 定。公司董事长李能、总经理游永平、时任董事会秘书肖巧霞未能恪尽职守、履行忠实勤勉义务，违反 了本所《股票上市规则（2024年修订）》第1.4条、第2.1.2条、第4.3.1条、第4.3.5条的规定，对上述违 规行为负有主要责任。 具体情况如下，2024年9月至2024年12月，公司与广东共合医药有限公司（以下简称共和医药）开展中 成药交易，相关关联交易涉及金额约875.58万元，占公司最近一期经审计净资产的1.15%。公司总经理 游永平关系密切的家庭成员刘莉民时为共和医药的控股股东，共和医药系公司关联法人。上述关联交易 未按规定履行相关决策程序和信息披露义务。 近日，嘉应制药（002198）发布公告称，公司及相关人员近日收到中国中国证券监督管理委员会广东监 管局《关于对广东嘉应制药股份有限公司、李能、游永平、史俊平、肖巧霞采取出具警示函措施的决 定》（〔2025〕128号）。 ...

Core Viewpoint - Green Leaf Pharmaceutical has received FDA approval to conduct clinical trials for its new generation 5-HT2A receptor inverse agonist and 5-HT2C receptor antagonist, LY03017, aimed at treating psychiatric disorders associated with Alzheimer's disease, Parkinson's disease, and negative symptoms of schizophrenia [1] Group 1: Clinical Development - LY03017 is based on the company's new molecular entity technology platform and is being developed simultaneously in China and the United States for central nervous system treatments [1] - The FDA has waived the single-dose escalation trial phase in the Phase I clinical trial, allowing the company to directly initiate multiple-dose escalation and subsequent clinical trials [1] - LY03017 is currently in Phase I clinical trials in China as well [1] Group 2: Market Opportunity - There is currently only one drug approved by the FDA for the treatment of Parkinson's disease psychosis (PDP), which has not yet been approved in China [1] - No drugs have been approved for the treatment of Alzheimer's disease psychosis (ADP) in both domestic and international markets [1] - Only a few drugs are effective for negative symptoms of schizophrenia (NSS), but their efficacy is suboptimal, indicating a significant unmet medical need in these three indications [1]

Core Viewpoint - China Merchants Bank has received approval from the National Financial Regulatory Administration for the establishment of its wholly-owned subsidiary, China Merchants Financial Asset Investment Co., Ltd, which will focus on market-oriented debt-to-equity swaps and equity investment pilot projects to enhance its operational capabilities and support high-quality development [1][3]. Group 1 - The registered capital of China Merchants Financial Asset Investment Co., Ltd is RMB 15 billion [1][3]. - The establishment of this subsidiary aims to deepen the synergy between industry and finance, as well as enhance group collaboration to better serve the real economy [1][3]. - The company plans to actively engage in pilot equity investment projects to empower technological innovation [1][3].

Core Viewpoint - GAC Group emphasizes its commitment to global automotive market trends by enhancing its differentiated brand and product matrix to improve overall competitiveness and risk resistance [1] Group 1: Product and Brand Development - The company has established a comprehensive product matrix covering various power forms, including fuel, pure electric, range-extended, and plug-in hybrid vehicles, under its own brands such as Trumpchi, Aion, and Haobo, as well as the Huawei collaboration brand, Qijing [1] - The focus is on electrification, intelligence, and premiumization to meet diverse consumer needs [1] Group 2: Robotics Initiatives - GAC Group has launched several advanced robotics, including the second-generation wheeled robot GoMove, service robot GoSide, and third and fourth-generation humanoid robots GoMate and GoMate Mini [1] - A global demonstration area for humanoid robots is planned to be established in Guangzhou by the end of 2025, with commercial model validation expected by 2026 and large-scale production targeted for 2027 [1] - The company aims to achieve a robotics industry chain output value exceeding 1 billion yuan by 2030 [1] Group 3: Financial Performance - For the period from January to September 2025, GAC Group reported revenues of 66.272 billion yuan, a year-on-year decrease of 10.49% [1] - The company experienced a net loss of 4.312 billion yuan, with losses expanding by 3691.33% year-on-year [1]

Core Viewpoint - China Jinmao announced the sale of its 100% stake in Jinmao (Sanya) Tourism Co., Ltd. for asset securitization, with a listing price of 2.265 billion yuan [1][3] Group 1: Sale Details - The sale is being conducted through the Beijing Property Exchange, with a listing price set at 2.265 billion yuan [1][3] - The target company primarily holds the Ritz-Carlton Hotel in Sanya, which opened in 2008 and features 446 guest rooms and suites, including 51 executive rooms and suites, a 450-square-meter executive lounge, and 33 private villas [1] - As of November 21, 2023, China Jinmao has not yet determined the buyer for the 100% stake or entered into any binding agreements [1] Group 2: Financial Performance - As of August 31, 2025, Jinmao (Sanya) Tourism Co., Ltd. is projected to have an operating income of approximately 236 million yuan and a net profit of 37.7799 million yuan [1] Group 3: Strategic Context - China Jinmao is accelerating its pace of hotel asset divestiture, having previously sold the Hilton Hotel in Sanya last year [1]

Core Viewpoint - Recently, Baicheng Pharmaceutical announced a collaboration with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the exclusive authorization of the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1: Collaboration Details - The collaboration involves a technical development cooperation agreement and a supplementary agreement, which will take effect after approval by the company's shareholders' meeting [1] - The agreement is classified as a related party transaction due to the involvement of Feng Enguang, the legal representative and senior management of Zhongshen Innovation, who previously served as the deputy general manager of Baicheng Pharmaceutical [1] Group 2: Regulatory Compliance - The transaction is in accordance with the Shenzhen Stock Exchange's Growth Enterprise Market Listing Rules, which define individuals who have served as senior management within the past twelve months as related natural persons [1]

Group 1 - The core viewpoint of the articles is that Angli Education is acquiring Shanghai Leyou International Travel Agency to achieve strategic and business synergies, focusing on the aging population and the silver economy as a growth avenue [1][2] - Angli Education's main business is in education and training, and the acquisition aims to provide personalized travel services for the elderly, enhancing the company's silver economy business [1] - Shanghai Leyou is one of the top three local travel agencies in Shanghai, with a strong market reputation and a customer base that is over 70% elderly, which aligns with Angli Education's target demographic for its "Happy Community" initiative [1] Group 2 - As of June 2025, Shanghai Leyou reported a negative net asset value of 9.1295 million yuan, indicating insolvency, with revenues of 65.9225 million yuan and 38.6414 million yuan for 2024 and the first half of 2025, respectively, both showing net losses [2] - Despite the losses, the equity value of Shanghai Leyou is assessed at 38.5 million yuan, reflecting an appreciation of 47.6295 million yuan, with a growth rate of 521.71% [2] - For the first three quarters of 2025, Angli Education achieved a revenue of 1.081 billion yuan, a year-on-year increase of 12.03%, and a net profit of 46 million yuan, up 141.11% year-on-year, attributed to improved operational efficiency [2]